Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
May 03 2019 - 8:30AM
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it
will report first quarter financial results and provide a corporate
update on May 9, 2019. The company will also host a conference call
that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-347-6311 from the
United States or 1-323-994-2132 internationally approximately ten
minutes before the start of the call. The passcode will be
4773625.
A replay will be available through May 23, 2019
at 888-203-1112 in the United States and 719-457-0820
internationally. The passcode will be 4773625.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in
the discovery and development of drugs that treat severe metabolic,
oncologic and psychiatric disorders by modulating the effects of
the stress hormone cortisol. The company’s product, Korlym®, was
the first FDA-approved treatment for patients with Cushing’s
syndrome. Korlym inhibits the effects of excess cortisol by
modulating activity at the glucocorticoid receptor, one of the two
receptors to which cortisol binds. Corcept has discovered a large
portfolio of proprietary compounds that selectively modulate the
effects of cortisol but not progesterone. It owns extensive United
States and foreign intellectual property covering the composition
of these selective cortisol modulators and the use of cortisol
modulators, including Korlym, to treat a wide variety of serious
disorders.
CONTACT:Christopher S. James, MDDirector,
Investor RelationsCorcept
Therapeutics650-684-8725cjames@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Sep 2023 to Sep 2024